A Safety Study of Pentoxifylline for the Treatment of Anemia
Status:
Terminated
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
Chronic kidney disease (CKD) patients have increased levels of inflammation and oxidative
stress, which in turn contribute to anemia and cardiovascular disease.
Pentoxifylline is known to have anti-inflammatory and anti-oxidant properties, and has shown
promise in improving the treatment of patients with anemia. This study will examine the use
of pentoxifylline for the treatment of anemia in chronic kidney disease.